190 related articles for article (PubMed ID: 35339689)
1. Key benefits of dexamethasone and antibody treatment in COVID-19 hamster models revealed by single-cell transcriptomics.
Wyler E; Adler JM; Eschke K; Teixeira Alves G; Peidli S; Pott F; Kazmierski J; Michalick L; Kershaw O; Bushe J; Andreotti S; Pennitz P; Abdelgawad A; Postmus D; Goffinet C; Kreye J; Reincke SM; Prüss H; Blüthgen N; Gruber AD; Kuebler WM; Witzenrath M; Landthaler M; Nouailles G; Trimpert J
Mol Ther; 2022 May; 30(5):1952-1965. PubMed ID: 35339689
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY
Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646
[TBL] [Abstract][Full Text] [Related]
3. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
Mühlemann B; Thibeault C; Hillus D; Helbig ET; Lippert LJ; Tober-Lau P; Schwarz T; Müller MA; ; Witzenrath M; Suttorp N; Sander LE; Drosten C; Jones TC; Corman VM; Kurth F
Clin Microbiol Infect; 2021 Oct; 27(10):1520.e7-1520.e10. PubMed ID: 34139335
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.
Sasaki M; Sugi T; Iida S; Hirata Y; Kusakabe S; Konishi K; Itakura Y; Tabata K; Kishimoto M; Kobayashi H; Ariizumi T; Intaruck K; Nobori H; Toba S; Sato A; Matsuno K; Yamagishi J; Suzuki T; Hall WW; Orba Y; Sawa H
EBioMedicine; 2024 Jan; 99():104950. PubMed ID: 38159532
[TBL] [Abstract][Full Text] [Related]
5. Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection.
Elizagaray ML; Mazitelli I; Pontoriero A; Baumeister E; Docena G; Raimondi C; Correger E; Rumbo M
Biomed J; 2023 Feb; 46(1):81-92. PubMed ID: 35948250
[TBL] [Abstract][Full Text] [Related]
6. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
[TBL] [Abstract][Full Text] [Related]
8. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
Olajide OA; Iwuanyanwu VU; Lepiarz-Raba I; Al-Hindawi AA
Inflammation; 2021 Oct; 44(5):1865-1877. PubMed ID: 33860869
[TBL] [Abstract][Full Text] [Related]
11. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
Dinda B; Dinda M; Dinda S; De UC
Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?
Kino T; Burd I; Segars JH
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201797
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
Orienti I; Gentilomi GA; Farruggia G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471278
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome.
Świerczek A; Jusko WJ
J Pharmacol Exp Ther; 2023 Mar; 384(3):455-472. PubMed ID: 36631280
[TBL] [Abstract][Full Text] [Related]
16. Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
Abdurrahman L; Fang X; Zhang Y
Curr Mol Med; 2022; 22(7):621-639. PubMed ID: 34645374
[TBL] [Abstract][Full Text] [Related]
17. Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019.
Koeckerling D; Barker J
J Infect Dis; 2021 Sep; 224(6):934-937. PubMed ID: 34157110
[TBL] [Abstract][Full Text] [Related]
18. Review of Anti-inflammatory and Antiviral Therapeutics for Hospitalized Patients Infected with Severe Acute Respiratory Syndrome Coronavirus 2.
Chen JT; Ostermann M
Crit Care Clin; 2022 Jul; 38(3):587-600. PubMed ID: 35667745
[TBL] [Abstract][Full Text] [Related]
19. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
[TBL] [Abstract][Full Text] [Related]
20. Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment.
Que H; Hong W; Lan T; Zeng H; Chen L; Wan D; Bi Z; Ren W; Luo M; Yang J; He C; Zhong A; Wei X
Signal Transduct Target Ther; 2022 Dec; 7(1):399. PubMed ID: 36566328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
